Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

News · September 20, 2022

EADV 2022: Lebrikizumab Efficacious in Moderate-to-Severe Atopic Dermatitis

16-week results demonstrate favorable response versus placebo as assessed by IGA, EASI-75, and Pruritus NRS

PracticeUpdate Editorial Team


Further Reading